Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials

source extracted confidence: high 2026-04-09
#anti-inflammatory-agents #biomarkers #cardiovascular-diseases #dietary-supplements #humans

Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials

Teimouri et al., 2022 | Complement Ther Med | Meta Analysis

Citation

Teimouri Maryam, Homayouni-Tabrizi Masoud, ... Hosseini Hossein. Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2022-Nov;70:102863. doi:10.1016/j.ctim.2022.102863

Abstract

BACKGROUND: Chronic inflammation is one of the most important factors involved in the development and progression of cardiovascular disease (CVDs). Accumulating evidence has described the effect of resveratrol, a natural polyphenolic compound, on biomarkers of inflammation among patients with CVDs; however, findings are controversial. Here we performed a systematic review and meta-analysis of randomized controlled trials to evaluate the effect of resveratrol supplements on TNF-α, IL-6, and CRP levels in CVDs patients. METHODS: Online research was conducted in the following database: MEDLINE, EMBASE, Cochrane Library, Web of Science databases, and Scopus. This systematic review and meta-analysis were conducted to investigate the effects of resveratrol supplements on inflammatory biomarkers among patients with CVDs. The meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V3 software. RESULTS: Six RCTs met the inclusion criteria and were selected for the current meta-analysis. Our results demonstrated that resveratrol significantly decreases serum levels of CRP (MD = -0.63, 95 % CI: -0.1.13, -0.12; p = 0.01), and TNF-α (MD = -0.55, 95 % CI: -1.04, -0.06; p = 0.02), however, resveratrol had not significant effect on serum concentration of IL-6 (MD = -0.12, 95 % CI: -0.52, 0.27; p = 0.53), in patients with CVDs. CONCLUSION: Our results suggest that resveratrol can be used as a potential treatment in patients with CVD by reducing inflammatory conditions.

Key Findings

Six RCTs met the inclusion criteria and were selected for the current meta-analysis. Our results demonstrated that resveratrol significantly decreases serum levels of CRP (MD = -0.63, 95 % CI: -0.1.13, -0.12; p = 0.01), and TNF-α (MD = -0.55, 95 % CI: -1.04, -0.06; p = 0.02), however, resveratrol had not significant effect on serum concentration of IL-6 (MD = -0.12, 95 % CI: -0.52, 0.27; p = 0.53), in patients with CVDs.

Outcomes Measured

  • C-reactive protein
  • inflammatory markers

Population

Field Value
Population cvds
Sample Size See abstract
Age Range See abstract
Condition inflammation

MeSH Terms

  • Anti-Inflammatory Agents
  • Biomarkers
  • Cardiovascular Diseases
  • Dietary Supplements
  • Humans
  • Inflammation
  • Interleukin-6
  • Randomized Controlled Trials as Topic
  • Resveratrol
  • Tumor Necrosis Factor-alpha

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis, Systematic Review
  • Vertical: resveratrol

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09